Loading clinical trials...
Loading clinical trials...
A 2-arm Randomized Phase II Study of Carboplatin, Paclitaxel Plus Reovirus Serotype-3 Dearing Strain (Reolysin) vs. Carboplatin and Paclitaxel in the First Line Treatment of Patients With Recurrent or Metastatic Pancreatic Cancer
Conditions
Interventions
Carboplatin
Laboratory Biomarker Analysis
+2 more
Locations
6
United States
MedStar Georgetown University Hospital
Washington D.C., District of Columbia, United States
Emory University/Winship Cancer Institute
Atlanta, Georgia, United States
Montefiore Medical Center-Weiler Hospital
The Bronx, New York, United States
Montefiore Medical Center - Moses Campus
The Bronx, New York, United States
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States
Start Date
December 1, 2010
Primary Completion Date
January 19, 2016
Completion Date
January 20, 2016
Last Updated
March 9, 2018
NCT02600949
NCT06921928
NCT06423326
NCT07542041
NCT06821997
NCT07076121
Lead Sponsor
National Cancer Institute (NCI)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions